We interviewed patients in 2009-2010 and obtained information from medical charts.Half of the women eligible for genomic testing for breast cancer recurrence risk received it. The most common reason for not getting the test was that women's physicians did not offer it (80%). Test recipients ...
Molecular profiling tests are "one of the most exciting things" going on in medical oncology, Dr Cyr said, and more data are forthcoming on the various tests for breast cancer. "The Oncotype DX test is somewhere between helpful and extremely helpful," said Michael Stone, MD, a medical oncol...
Genomic testing in early-stage hormone-positive breast cancer is the standard of care. However, decisions based on genomic testing results are predicated on the assumption that patients receive endocrine treatment. We sought to investigate racial differences in genomic testing and adjuvant treatment in ...
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars PartnersPublications Resources Interactive ToolsSponsored Biomarker ConsortiumSubscribe Choose Specialty Biosimilars Brain Cancer Breast CancerBreast Cancer ...
METHOD: We interviewed 163 stage I or II breast cancer patients at a routine follow-up appointment. We assessed their health literacy (using the Rapid Estimate of Adult Learning in Medicine) as well as their knowledge of and attitudes towards a genomic test that identifies risk of recurrence ...
Once you have decided on our breast cancer genomic testing - MammaPrint can be ordered alone or in combination with BluePrint.
of co-regulated imprinted genes26,44, withPLAGL1as putative key player26,45,46,47. Results from preliminary analyses (Supplementary Note7) are compatible with the presence of an imprinted gene network in cancer as well, but an elaborated co-expression analysis is required to formally test this...
EndoPredict (EP) is a clinically validated multianalyte gene expression test to predict distant metastasis in ER-positive, HER2-negative breast cancer treated with endocrine therapy alone. The test is based on the combined analysis of 12 genes in formalin-fixed, paraffin-embedded (FFPE) tissue by...
Racial disparities in breast cancer outcomes remain a persistent challenge.1Earlier onset, advanced stage at diagnosis, aggressive tumor subtype (eg, triple-negative breast cancer), and shorter survival are characteristic features of breast cancer in Black patients compared with their White counterparts,...
Kaplan-Meier analysis was used for calculation and visualization of survival curves, and Cox-regression models followed by Wald test were used to determine the statistical association between the expression of each miRNA and distant metastases free survival (DMFS) or breast cancer specific survival (B...